INFO & CONTACTS:  +39 02 2390 1

A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Phase: Phase III clinical trials

Principal Investigator: Dott.ssa Bianchi Giulia Valeria

Main Facility: Oncologia Medica Senologica

Drug: Pumitamig (indicato anche come BNT327 o PM8002)

Pathologies: Breast cancer (TNBC)

ClinicalTrials.gov: Read the details about clinical trials

A randomized 1:1 Phase III clinical trial evaluating Pumitamig (a bispecific antibody targeting PD-L1 and VEGF-A) compared with placebo in patients with previously untreated, locally recurrent inoperable or metastatic triple negative breast cancer (TNBC).

Last update: 14/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe